GlobeNewswire

Bioventus Reports Third Quarter Financial Results
02/11/2026
Q3 reported revenue of $142.4 million increased 3% Q3 GAAP earnings of $0.08 per diluted share compared to the prior-year period earnings of $0.05 per diluted share Non-GAAP earnings* of $0.17 per diluted share compared [...]
Relay Therapeutics to Participate in Three Upcoming Investor Conferences in November
02/11/2026
CAMBRIDGE, Mass., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living [...]
Atea Pharmaceuticals to Host Third Quarter 2026 Financial Results and Business Update Conference Call on November 9, 2026
02/11/2026
BOSTON, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a late-stage clinical biopharmaceutical company engaged in the discovery and development of oral antiviral [...]
Spero Therapeutics to Present at Investor Conferences in November
02/11/2026
CAMBRIDGE, Mass., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on advancing next-generation medicines in immune-mediated diseases, today [...]
OrthoPediatrics to Participate in Upcoming Conferences
02/11/2026
WARSAW, Ind., Nov. 02, 2026 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced [...]
Trevi Therapeutics to Report Third Quarter 2026 Financial Results and Provide a Corporate Update on November 9, 2026
02/11/2026
Conference call and webcast to be held at 4:30 p.m. ET NEW HAVEN, Conn., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the [...]
Regeneron Announces Investor Conference Presentations
02/11/2026
TARRYTOWN, N.Y., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) will webcast management participation as follows: 2026 Jefferies Global Healthcare Conference in London at 2:00 p.m. GMT [...]
Lakefront Biotherapeutics Welcomes Dr. Mehdi Shahidi to its Board of Directors
02/11/2026
Dr. Shahidi brings extensive drug development experience, regulatory success, and transformative operational expertise to the Board Mechelen, Belgium; November 2, 2026, 22.01 CET; Lakefront Biotherapeutics NV (Euronext [...]
Syndax Announces CFO Transition – Aaron A. Ondrey Appointed Chief Financial Officer
02/11/2026
- Keith A. Goldan to retire as CFO and remain with the Company through year-end to support the transition - NEW YORK, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage [...]
C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
02/11/2026
WATERTOWN, Mass., Nov. 02, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced [...]
Syndax Reports Third Quarter 2026 Financial Results and Provides Business Update
02/11/2026
– Total revenue of $83.3 million in 3Q26, an 82% year-over-year increase – – Revuforj ® (revumenib) net revenue of $60.7 million in 3Q26, a 90% y/y increase, underscores leadership in R/R NPM1m and KMT2Ar acute leukemia [...]
CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2026 Financial Results
02/11/2026
– CASGEVY ® revenue of $99 million in the third quarter of 2026, up 30% quarter-over-quarter and nearly six times the third quarter of 2025 – – CASGEVY approved in the U.K. for children 5 years of age and older with [...]
CVRx to Participate in Upcoming Investor Conferences
02/11/2026
MINNEAPOLIS, Nov. 02, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions [...]
Dianthus Therapeutics to Participate in Five Investor Conferences During November
02/11/2026
NEW YORK and WALTHAM, Mass., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the [...]
Xenon to Report Q3 2026 Financial Results on November 9, 2026
02/11/2026
VANCOUVER, BC and BOSTON, MA, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and [...]
Assembly Biosciences to Participate in Upcoming Investor Conferences
02/11/2026
SOUTH SAN FRANCISCO, Calif., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral and liver diseases, today [...]
Avalo Therapeutics to Participate in Upcoming Investor Conferences
02/11/2026
WAYNE, Pa., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company dedicated to developing therapeutics targeting the IL-1β pathway for immune-mediated [...]
Report on transactions with ALK-Abelló A/S B shares and associated securities by managerial staff
02/11/2026
ALK (ALKB:DC / Nasdaq Copenhagen: ALK B): In accordance with article 19 in Regulation (EU) No 596/2014 of 16 April 2014 on market abuse (the Market Abuse Regulation), ALK-Abelló A/S shall report the following [...]
Coloplast A/S Announcement no. 11/2026 - 2025/26 Full-Year Financial Results
02/11/2026
1 October 2025 - 30 September 2026 Coloplast delivered 5% organic growth in Q4, driven by continued strength in Chronic Care and Interventional Urology. EBIT growth 1 in constant currencies was 0% and includes negative [...]

Pages

Other news

Test 2

Lorem ipsum

Test 1

Lorem upsum